|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500099606 |
|
最近更新日期: Date of Last Refreshed on: |
2025-03-26 14:28:23 |
|
注册时间: Date of Registration: |
2025-03-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
rTMS联合强化感觉对MI-BCI干预脑卒中后运动障碍的神经功能重塑机制研究 |
|
Public title: |
The study of rTMS combined with sensory reinforcement on the neural function remodeling mechanism of MI-BCI intervention for motor dysfunction after stroke |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
rTMS联合强化感觉对MI-BCI干预脑卒中后运动障碍的神经功能重塑机制研究 |
|
Scientific title: |
The study of rTMS combined with sensory reinforcement on the neural function remodeling mechanism of MI-BCI intervention for motor dysfunction after stroke |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
林强 |
研究负责人: |
林强 |
|
Applicant: |
Qiang Lin |
Study leader: |
Qiang Lin |
|
申请注册联系人电话: Applicant telephone: |
+86 189 2249 7674 |
研究负责人电话:
Study leader's |
+86 189 2249 7674 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
linqiang@sysush.com |
研究负责人电子邮件: Study leader's E-mail: |
linqiang@sysush.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省深圳市光明新区新湖街道圳园路628号 |
研究负责人通讯地址: |
广东省深圳市光明新区新湖街道圳园路628号 |
|
Applicant address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, Guangdong, China |
Study leader's address: |
No.628, Zhenyuan Rd, Guangming (New) Dist, Shenzhen, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中山大学附属第七医院(深圳) |
||
|
Applicant's institution: |
The Seventh Affiliated Hospital of Sun Yat-sen Universit(Shenzhen) |
||
|
研究负责人所在单位: |
中山大学附属第七医院(深圳) |
||
|
Affiliation of the Leader: |
The Seventh Affiliated Hospital of Sun Yat-sen Universit(Shenzhen) |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY-2024-338-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第七医院(深圳)医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-08 00:00:00 | ||
|
伦理委员会联系人: |
魏嘉亿 |
||
|
Contact Name of the ethic committee: |
Jiayi Wei |
||
|
伦理委员会联系地址: |
广东省深圳市光明区新湖街道圳美社区海鑫光高新工业园F栋1楼 |
||
|
Contact Address of the ethic committee: |
1 / F, Building F, Haixin High-tech Industrial Park, Zhenmei Community, Xinhu Street, Guangming District, Shenzhen, 1 / F, Building F, Haixin High-tech Industrial Park, Zhenmei Community, Xinhu Street, Guangming District, Shenzhen |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 755 8120 7260 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中山大学附属第七医院(深圳) |
||||||||||||||||||||||
|
Primary sponsor: |
The Seventh Affiliated Hospital of Sun Yat-sen Universit(Shenzhen) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省深圳市光明新区新湖街道圳园路628号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.628, Zhenyuan Rd, Guangming (New) Dist, Shenzhen, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
广东省自然科学基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Guangdong Province Natural Science Fund |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
Stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
阐明rTMS联合MI-BCI训练对脑卒中后运动功能障碍的神经重塑作用。 |
||||||||||||||||||||||
|
Objectives of Study: |
To clarify the effect of rTMS combined with MI-BCI training on neural remodeling of motor dysfunction after stroke. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
脑卒中患者 ① 全国第四次脑血管病学术会议制订的脑卒中诊断标准; ② 经头颅CT或MRI检查确诊为首次发病,病程≥6个月; ③ 年龄在18~80岁之间,包括18岁和80岁,性别不限; ④ 上肢和手存在脑卒中后运动功能障碍; ⑤ 生命体征平稳; ⑥ 所有患者均签署治疗知情同意书。 健康受试者 ① 身体健康状况良好; ② 年龄在18~80岁之间,包括18岁和80岁,性别不限。 ③ 所有受试者均签署治疗知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
Patients with stroke 1 The diagnostic criteria of stroke formulated by the Fourth National Conference on Cerebrovascular Disease; 2 The first attack was confirmed by head CT or MRI examination, and the course of disease was more than 6 months; 3 age between 18 and 80 years old, including 18 and 80 years old, regardless of gender; 4 motor dysfunction of upper limbs and hands after stroke; 5 stable vital signs; 6 All patients signed the informed consent for treatment. Healthy subjects 1 Good physical health; 2 Age between 18 and 80 years old, including 18 years old and 80 years old, regardless of gender. 3 All subjects signed the informed consent for treatment. |
||||||||||||||||||||||
|
排除标准: |
① 严重认知功能障碍或精神疾患等原因导致无法理解指令,且无法配合; ② 有癫痫病史; ③ 患有其他影响功能恢复的肌肉骨骼和神经系统疾病; ④ 有恶性肿瘤、严重心、肝、肺、肾功能不全及内分泌、造血、免疫系统等严重原发性疾病; ⑤ 既往有上肢骨折、严重关节炎、关节置换术等影响上肢功能。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1 Inability to understand and cooperate with instructions due to severe cognitive impairment or mental disorder; 2 History of epilepsy; 3 other musculoskeletal or neurological disorders affecting functional recovery; 4 malignant tumors, severe heart, liver, lung, kidney dysfunction, endocrine, hematopoietic, immune system and other serious primary diseases; 5 Previous upper limb fractures, severe arthritis, and joint replacement surgery affected upper limb function. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-04-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-04-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表法。 在此研究中,由研究者事先分别从1到30为每位脑卒中患者依次进行编号,确保每位患者有且只有一个编号;使用EXCEL为每位患者生成各自的随机数,将患者的各自随机数从小到大进行排序号(随机数相同的按照患者编号顺序进行排序);规定序号1~10的患者分配至S1+MI-BCI组,序号11~20的患者分配至M1+MI-BCI组,序号21~30的患者分配至假刺激+MI-BCI组。再从31-60为每位健康受试者依次进行编号,确保每位受试者有且只有一个编号;使用EXCEL为每位受试者生成各自的随机数,将受试者的各自随机数从小到大进行排序号(随机数相同的按照患者编号顺序进行排序);规定序号31~40的患者分配至S1+MI-BCI组,序号41~50的患者分配至M1+MI-BCI组,序号51~60的患者分配至假刺激+MI-BCI组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number table method. In this study, the researchers numbered each stroke patient from 1 to 30 in order to ensure that each patient had one and only one number. EXCEL was used to generate their own random numbers for each patient, and the patient's random numbers were sorted from small to large (the same random numbers were sorted according to the patient number order). Patients with specified serial numbers 1 to 10 were assigned to the S1+MI-BCI group, patients with serial numbers 11 to 20 were assigned to the M1+MI-BCI group, and patients with serial numbers 21 to 30 were assigned to the sham-stimulation +MI-BCI group. Then each healthy subject was numbered from 31 to 60 to ensure that each subject had one and only one number. EXCEL was used to generate their own random numbers for each subject, and the subjects' respective random numbers were sorted from small to large (the same random numbers were sorted according to the patient number order). Patients with specified serial numbers 31 to 40 were assigned to the S1+MI-BCI group, patients with specified serial numbers 41 to 50 were assigned to the M1+MI-BCI group, and patients with specified serial numbers 51 to 60 were assigned to the sham-stimulation +MI-BCI group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:由研究者采用病例记录表(Case Record Form, CRF)进行 数据管理:由研究者专门进行数据管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: the researchers adopt Case Record Form(CRF) Data management, data management by the researchers |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |